Navigation Links
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Date:10/11/2010

RARITAN, N.J., Oct. 11 /PRNewswire/ -- Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo. This study included 1,195 patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer, or CRPC) previously treated with one or two chemotherapy regimens, at least one of which contained docetaxel.  

The results of this randomized, placebo-controlled study were shared during a late-breaking presentation at the Presidential Symposium today at the 35th Annual European Society for Medical Oncology (ESMO) Congress.

Treatment with abiraterone acetate resulted in a 35 percent reduction in the risk of death (HR=0.65; 95 percent CI: 0.54, 0.77; p<0.0001) and a 36 percent increase in median survival (14.8 months vs. 10.9 months) compared with placebo.

Patients who received abiraterone acetate and low-dose prednisone/prednisolone also showed significant improvements in secondary study endpoints when compared to the prednisone/prednisolone plus placebo group: time to PSA progression (TTPP) [median 10.2 months for abiraterone acetate vs. 6.6 months for placebo, HR=0.58 (95 percent CI: 0.46, 0.73); p<0.0001] and an increase in radiographic progression-free survival (rPFS) [median 5.6 months for abiraterone acetate vs. 3.6 months for placebo, HR=0.67 (95 percent CI: 0.58, 0.78); p<0.0001].  Total PSA response, defined as greater than or equal to a 50 percent decrease from baseline, was achieved in 38 percent of patients treated with abiraterone acetate vs. 10 percent in the prednisone/prednisolone plus placebo group [p<0.0001].  

Patients in the abiraterone acetate group experience
'/>"/>

SOURCE Ortho Biotech Oncology Research & Development
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnsons Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
2. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
3. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
4. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
5. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
6. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
7. FDA Advisory Committee Unanimously Recommends Approval of HRA Pharmas Ulipristal Acetate for Emergency Contraception
8. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
9. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
(Date:4/17/2014)... find a colored ribbon representing a disease. A pink ribbon ... ribbon does one think of with lung cancer?, Although white ... from the disease, black may be the only one they ... cancer patients, primarily smokers between the ages of 51 to ... often felt by these patients, the emotional toll it can ...
(Date:4/17/2014)... A new study has found that India,s shocking rates ... debt-ridden farmers who are clinging to tiny smallholdings ... ,cash crops, such as cotton and coffee, that are ... supports a range of previous case studies that point ... sector following the ,liberalisation, of the nation,s economy during ...
(Date:4/17/2014)... anti-malarial treatment that lost its status as the leading ... new lease of life, with new research indicating it ... could revive the use of the cheap anti-malarial drug ... claims the lives of more than half a million ... that causes malaria has developed resistance to chloroquine, but ...
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
Breaking Medicine News(10 mins):Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... becoming apparent to the Government Health officials, albeit for the ... socks and gearing up to take stock of multi-drug resistant ... a public health initiative , developed by the World Health ... in Maharashtra and Gujarat. 100 MDR-TB cases are envisaged in ...
... at The University of Texas M. D. Anderson Cancer ... prostate cancer patients who are eligible for watchful // ... ,"With the advent of the PSA test, we ... no evidence that early detection means longer survival. Because ...
... recent progress in echocardiography providing doctors with improved imaging ... a // probe into the esophagus, which emits radio ... in enabling a motion picture of the heart, far ... images are capable of offering various options to doctors ...
... women who present to the sex clinic only report ... some women, may present with just the opposite complaints//. ... suffering from the so-called persistent sexual arousal syndrome (PSAS) ... ,Currently, very little is understood about this rare syndrome ...
... you badly in need of blood or are you inclined in ... it//? Either way, the solution for it is just a few ... simple yet amazingly useful venture in 2000. He works for Central ... of the venture too. ,If you're located in Kolkata ...
... is a mere 0.028 percent as compared to the national ... further, the military's top doctor said Thursday. ,"Contracting ... crime," Surgeon Vice Admiral Vijay K. Singh, director general of ... ,The national average of the incidence of HIV/AIDS ...
Cached Medicine News:Health News:New Network To Ease Blood donation In India 2Health News:Incidence Of HIV/AIDS In The Indian Armed Forces Negligible 2
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Medicine Products: